Stock Quote
Mylan Inc. (MYL.O) (Nasdaq)
$17.98
4:00pm EST
+2.45%
$17.55
$17.74
9,648,453
$18.08
$17.65
$18.10
$7.69
0.54
5,433,316
MYL.O
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Coury, Robert | Chairman of the Board, Chief Executive Officer | 12,475,094 |
| Bresch, Heather | President | 2,973,426 |
| Piatt, Rodney | Vice Chairman of the Board | -- |
Profile
Mylan Inc. (Mylan) and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). As of May 5, 2009, the Company held a 71.2% interest... Full Description
Company Address
Mylan Inc.
1500 Corporate Drive
Suite 400
Canonsburg PA 15317
P: +1724.5141800
F: +1724.5141870
1500 Corporate Drive
Suite 400
Canonsburg PA 15317
P: +1724.5141800
F: +1724.5141870
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Pfizer Inc. | $18.53 | +0.17 |
| Johnson & Johnson | $62.69 | +0.38 |
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| MYL.O | Industry | |
|---|---|---|
| P/E(TTM) | 109.07 | 3.57 |
| P/S(TTM) | 1.08 | 0.57 |
| ROI(TTM) | 2.11 | 1.86 |
| ROE(TTM) | 1.64 | 2.51 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.34 |
| EPS Est. (Current Year) | 1.25 |
| Total Revenue | $1,264.07M |
| Net Income | $-4.42M |
| EPS | $-0.13 |
